Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 51,308

Document Document Title
WO/2016/019847A1
The present invention relates to a fluorine substituted dabigatran ester derivative as indicated in formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a use thereof in preparing medications for preven...  
WO/2016/021602A1
The purpose of the present invention is to provide a liquid immunity induction-promoting composition and a vaccine pharmaceutical composition that are capable of being universally used for liquid immunity induction against a variety of a...  
WO/2016/019848A1
A dabigatran thioester derivative as indicated in formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a use thereof in preparing medications for preventing and treating thromboembolic diseases, X1, X2, R1...  
WO/2016/020345A1
The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.  
WO/2016/022656A1
This invention relates to methods of treating sickle cell disease with VLA-4 antagonists and methods for evaluating the responsiveness of patients having sickle cell disease to treatment with VLA-4 antagonists.  
WO/2016/019849A1
A dabigatran carboalkoxy derivative as indicated in formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a use thereof in preparing medications for preventing and treating thromboembolic diseases, all subs...  
WO/2016/020080A1
Edoxaban is factor X inhibitor useful for the treatment or the prevention of thrombosis or embolism. A pharmaceutical composition comprising Edoxaban, or a pharmaceutically acceptable salt thereof, a water soluble vinylpyrrolidone polyme...  
WO/2016/019844A1
The present invention relates to a dabigatran cyclic ester derivative, as represented by formula (I), and a stereoisomer or pharmaceutically acceptable salt thereof, as well as a use thereof in the preparation of a pharmaceutical used fo...  
WO/2016/019846A1
The present invention relates to a dabigatran ester derivative, and a stereoisomer or pharmaceutically acceptable salt thereof, as well as a use thereof in the preparation of a pharmaceutical used for prevention and treatment of a thromb...  
WO/2016/022521A1
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders assoc...  
WO/2016/016907A1
The present invention relates to novel polymorphs of (lS,2S,3R,5S)-3-[7-{[(lR,2S)-2- (3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[l, 2,3]-triazolo[4,5-d]pyrimidi yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol represented by th...  
WO/2016/018702A1
The present invention provides a compound of Formula (I) (Formula(I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoag...  
WO/2016/018701A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...  
WO/2016/019226A1
Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (PRR) antagonist. In some instances the PRR antagonist is a polypeptide. T...  
WO/2016/015593A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...  
WO/2016/011940A1
The present invention relates to an indole-amide derivative, a preparation method therefor and an application thereof in medicine. Specifically, the present invention relates to an indole-amide derivative represented by general formula (...  
WO/2016/014778A1
Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.  
WO/2016/012595A1
The present invention relates to pharmaceutical preparations comprising two-chain Factor VIII that are essentially free of Factor Vlll-Light Chains (FVIII-LCs) which are not associated with Factor Vlll-Heavy Chains (FVIII-HCs) having hig...  
WO/2016/011301A1
Embodiments of the present disclosure generally relate to materials and methods for modulating blood coagulation. In certain embodiments, the present disclosure provides materials and methods for modulating assembly and function of prote...  
WO/2016/010014A1
[Problem] To provide an anti-human Tie2 antibody which prevents or treats diabetic macular edema, diabetic retinopathy, or critical limb ischaemia by binding to human Tie2 and activating human Tie2. [Solution] The inventors of the presen...  
WO/2016/009405A1
The present invention relates to new crystalline compounds of dabigatran etexilate, namely to crystalline compounds comprising mixtures of dabigatran etexilate and an acid. The invention also relates to processes for the preparation of t...  
WO/2016/011381A1
Provided herein are methods of enhancing engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing expression (or activity) of CXC chemokine receptor 4 (CXCR4). Such methods can be used in gene therapy protocols and...  
WO/2016/010108A1
A compound represented by formula (I) [in the formula: (1) represents (2), (3), etc.; R2a represents optionally substituted alkyl, etc.; R2b, R3a, R3b, R4a, R4b, R5a and R5b independently represent a hydrogen atom, etc.; and R1 represent...  
WO/2016/008064A1
Compounds of Formula I and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medi...  
WO/2016/005560A1
The present invention relates to a novel process for the manufacture of 1-(4- methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6 ,7-tetrahydro-1 H- pyrazolo[3,4-c]pyridine-3-carboxamide and pharmaceutically acceptable salts the...  
WO/2016/004894A1
Provided are biocompatible iron oxide nanoparticles and a method of treating a condition related to iron deficiency. Said biocompatible iron oxide nanoparticles each contains an iron oxide core that is covered by one or more biocompatibl...  
WO/2016/005981A1
The present invention is directed to mi R-122 and regulation of expression thereof. Further provided are compositions comprising mi R-122 modulators and uses thereof for affecting expression of EPO, and for treating various related condi...  
WO/2016/005599A1
The present specification discloses compositions comprising at least one therapeutic compound capable of modulating a level and/or activity of a hormone and methods and uses for treating a gender-biased immune disorder using such composi...  
WO/2016/000616A1
The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or ...  
WO/2016/000039A1
The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least a modification at position 1 or 3 such that the...  
WO/2015/199039A1
Provided are a synthetic peptide having multinucleation-inducing activity capable of causing multinucleation in a target cell, a multinucleation inducing agent including the peptide, and a multinucleation inducing method using the peptid...  
WO/2015/199147A1
The present invention pertains to stabilization of a certain class of benzothia(dia)zepine derivative, in a solid preparation containing the derivative. According to the present invention, either the solid preparation containing the benz...  
WO/2015/199169A1
Provided is a composition that includes: a tea extract or a catechin; and a citrus fruit extract or a flavanone, or a glucoside thereof.  
WO/2015/199127A1
The present invention addresses the problem of providing: a novel method for producing mesodermal cells; and a graft material which contains mesodermal cells produced by the method. The present invention also addresses the problem of pro...  
WO/2015/193326A1
The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. T...  
WO/2015/194233A1
The present invention is based on the discovery that by administering a predetermined dosing regimen of a pharmaceutical composition that comprises a bi-specific antigen-binding molecule that recognizes blood coagulation factor IX and/or...  
WO/2015/191899A9
The present disclosure relates to methods, systems, and compositions to repair one or more mutations in a Factor VIII gene sequence of a subject by introducing into a cell of the subject one or more polynucleotides encoding a DNA scissio...  
WO/2015/188787A1
Provided are a novel preparation method of an oxazolidinone compound, and several important intermediates involved in the method. The preparation method disclosed herein has the characteristics of cheap raw material, mild conditions, sim...  
WO/2015/190573A1
[Problem] To provide a composition for preventing and/or improving iron-deficiency anemia, a composition for preventing and/or improving indefinite complaints associated with iron-deficiency anemia, a pharmacological composition for prev...  
WO/2015/191899A1
The present disclosure relates to methods, systems, and compositions to repair one or more mutations in a Factor VIII gene sequence of a subject by introducing into a cell of the subject one or more polynucleotides encoding a DNA scissio...  
WO/2015/188794A1
The present invention relates to a stable pharmaceutical formulation, containing fesoterodine [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4- (hydroxymethyl)phenyl] 2-methyl propanoate of formula (I) and/or its salts, solvate ester ...  
WO/2015/188073A1
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.  
WO/2015/185499A1
A 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbon itrile compound of the formula (I) wherein R1 is -COCH2R2, COO-C1-6-alkyl, CH2CONR3R4, pyridinyl, pyrimidinyl or C1-6-alkyl which is optionally substituted with C1-6-alkoxy, ...  
WO/2015/184981A1
An alprostadil composition and injection and lyophilization formulation comprising the same; the composition comprises alprostadil, oil for injection, phosphatidylcholine and phosphatidylinositol and is free of phosphatidylethanolamine; ...  
WO/2015/187704A1
Methods are provided for treating autoimmune disease in a subject by inhibiting the activity of DGAT1.  
WO/2015/180583A1
Substituted acetohydrazide derivatives represented by formula I, or pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts of formula I effectively inhibit prolyl hydroxylase, and have stable hypox...  
WO/2015/182121A1
Disclosed is a method for easily examining allergy-inducing properties. More specifically, a method for examining allergy-inducing properties of a test substance, said method comprising: A) a step for exposing alveolar macrophages in a t...  
WO/2015/180342A1
The present invention provides a deuterium substituted 1-[2-(2,4-dimethyl-thiophenyl)-phenyl] piperazine compound with a structure represented by formula (I) or a derivative thereof, a pharmaceutical composition containing the compound o...  
WO/2015/180485A1
The present invention relates to an amantadine nitrate compound having a neuroprotective effect and a preparation and a medical use thereof. The compound has the structure of the general formula (I). The compound has multiple mechanisms ...  
WO/2015/179958A1
Provided herein are polymers and methods for their use in binding a phosphate containing biological macromolecules. Specifically, the methods and uses provided herein may be used to inhibit thrombin binding to polyphosphate or as an anti...  

Matches 701 - 750 out of 51,308